Tiblio
Sign Up

FTH

Faeth Therapeutics, Inc.
NASDAQHEALTHCAREBIOTECHNOLOGY

Key Statistics

Market Cap
$666.90M
P/E Ratio
—
EPS
$-142.72
Beta
-0.26
52W High
$37.90
52W Low
$6.33
50-Day MA
$21.11
200-Day MA
$18.12
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—

About Faeth Therapeutics, Inc.

Faeth Therapeutics, Inc. is a pioneering biotechnology company focused on transforming cancer treatment through its innovative approach to immunotherapy. Leveraging advanced protein engineering and proprietary technologies, Faeth aims to enhance the body's natural defenses to target and eliminate cancer cells effectively. The company's robust pipeline includes promising candidates that address significant unmet medical needs in oncology, positioning Faeth as a key player in the evolving landscape of cancer therapeutics. With a dedicated management team and strong scientific expertise, Faeth Therapeutics is poised to make substantial strides in improving patient outcomes in the fight against cancer.

Official WebsiteUSAFY End: December

Fundamentals

Revenue (TTM)0
Gross Profit (TTM)0
EBITDA$-185.51M
Operating Margin0.00%
Return on Equity0.00%
Return on Assets-95.20%
Revenue/Share (TTM)$0.00
Book Value$-102.43
Price-to-Book1.26
Price-to-Sales (TTM)—
EV/Revenue-
EV/EBITDA1.36
Quarterly Earnings Growth (YoY)0.00%
Quarterly Revenue Growth (YoY)0.00%
Shares Outstanding$25.78M
Float$1.17M
% Insiders1.45%
% Institutions25.67%

Historical Volatility

HV 10-Day
160.51%
HV 20-Day
152.32%
HV 30-Day
156.69%
HV 60-Day
139.64%
HV Rank
—

Volatility is currently expanding

Analyst Ratings

Consensus ($54.50 target)
7
Buy

Latest News

Faeth Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

AUSTIN, Texas--(BUSINESS WIRE)--Faeth Therapeutics, Inc. (Nasdaq: FTH) today announced that the Compensation Committee of Faeth's Board of Directors granted six new employees options to purchase an aggregate of 180,350 shares of the Company's common stock in connection with their employment (collectively, the “Option Awards”). The Option Awards were granted pursuant to the Company's 2026 Inducement Plan as a material inducement to the individuals entering employment with Faeth in accordance wit.

Business Wire7/3/2026Neutral

Turn research into an automated options-selling system

Tiblio connects your broker and runs your put-and-call-writing strategy for you — on FTH and any ticker you trade — then tracks every position and per-strategy win rate.

See how it works

More HEALTHCARE Stocks

LLYEli Lilly and CompanyJNJJohnson & JohnsonABBVAbbVie IncUNHUnitedHealth Group IncorporatedMRKMerck & Company IncNVSNovartis AG ADRAZNAstraZeneca PLCNVONovo Nordisk A/STMOThermo Fisher Scientific IncAMGNAmgen IncABTAbbott LaboratoriesGILDGilead Sciences Inc
View all HEALTHCARE stocks →
Data last updated: 7/20/2026